Kelly John Alexander 4

What Happened
John Alexander, Chief Financial Officer of Precision Biosciences, received a grant of 193,688 restricted stock units (RSUs) on June 1, 2026. The RSUs were reported as acquired at $0.00 per unit (derivative award), meaning no cash was paid at grant; the units represent contingent rights to receive common shares if vesting conditions are met.

Key Details

• Transaction date: 2026-06-01; filing date: 2026-06-03 (Form 4 accession 0001628280-26-040215). Filing appears timely.
• Transaction type/code: A (Award/Grant) — 193,688 RSUs acquired at $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Each RSU converts to one share of common stock if vested (F1).
• Vesting: Award vests in three substantially equal annual installments beginning Feb 19, 2027, subject to continued service (F2).
• No sale, purchase for cash, tax withholding, or 10b5-1 plan noted in this filing.

Context
RSU grants are a common form of executive compensation and do not represent an immediate purchase or sale of stock; they only convert into actual shares if and when vesting conditions are satisfied. Because the grant was reported as a derivative award at $0 upfront, there is no immediate cash outlay or proceeds to the insider. Retail investors should view this as compensation alignment rather than a direct market signal; potential dilution occurs only as units vest and are settled into shares.